RxDoctor Payments Data

Reza Allamehzadeh, MD

Internal Medicine · Mission Viejo, CANPI 1467606053

Payments from drug & device makers

$77,969in general payments, 2019–2025

Across 42 payments — averaging $1856.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$59K
  • AstraZeneca$12K
  • Incyte Corporation$6K
  • Boston Scientific$84
  • Bayer$71
  • Calliditas Therapeutics US Inc.$47
  • plus $45 from 2 others

What the payments were for

  • Travel & lodging$1,16366%
  • Food & beverage$58233%
  • Education$272%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,969 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$802,616
Medicare patients
484
Services billed
16,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$171,095
JardianceEmpagliflozin138$166,992
ProliaDenosumab81$129,976
FarxigaDapagliflozin Propanediol149$118,754
JanuviaSitagliptin Phosphate142$118,505
LinzessLinaclotide114$109,570
EliquisApixaban92$104,687
MyrbetriqMirabegron108$99,396
VascepaIcosapent Ethyl151$90,068
TrulicityDulaglutide30$59,915
MounjaroTirzepatide38$41,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,620
TradjentaLinagliptin50$34,171
GemtesaVibegron37$33,794
Combivent RespimatIpratropium/Albuterol Sulfate28$33,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Symbicort$12,223$147,701190 claims
AmgenProlia$28$129,97681 claims
Sumitomo Pharma America, Inc.Gemtesa$17$33,79437 claims
BayerKerendia$71$12,95712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →